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Introduction
Neuroleptic malignant syndrome (NMS) as an adverse reaction to the 
use of atypical neuroleptics (AN) is present in 0.02 - 3 % of patients, 
being determined by age, sex, diagnosis and the group of atypical 
neuroleptics that were administered. 
Purpose
Analysis and systematization of the adverse 
reactions (neuroleptic malignant syndrome) 
produced by atypical neuroleptics.
Material and methods
The articles from the PubMed and MEDLINE database were selected 
and analyzed according to the keywords “neuroleptic malignant 
syndrome”, “atypical antipsychotic drugs”, “treatment of 
schizophrenia”.
Results
The pathophysiology of this adverse 
reaction is not fully elucidated, a 
hypothesis is the rapid blockade of D2 
receptors in the CNS. NMS includes such 
symptoms as: instability, 
extrapyramidal disorders, hyperpyrexia, 
and altered mental state. When using 
AN as clozapine, risperidone, 
olanzapine and quentiapine SNM 
occurred on average on the 14th day. 
Thus, on the background of the 
treatment with clozapine SNM was 
manifested in 30%, in the 
administration of risperidone in 38%, in 
the administration of olanzapine in 
27%, and quentiapine in 5% of cases. 
Conclusions
Thus, we can say that in terms of treatment with AN, the SNM 
rate is lower than with the use of typical neuroleptics or it may 
simply be a reflection of doctors' awareness and the follow-up of 
early treatment with more harmless and contemporary drugs.
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